Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 in Japanese HFpEF Patients
NCT03909295Phase 3Terminated
- Sponsor
- Novartis
- Start
- May 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF), sponsored by Novartis. Started May 2019; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03909295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909295.